GERN vs. FOLD, LGND, DVAX, MNKD, IRWD, INVA, OPK, ORGO, INZY, and FHTX
Should you be buying Geron stock or one of its competitors? The main competitors of Geron include Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), Dynavax Technologies (DVAX), MannKind (MNKD), Ironwood Pharmaceuticals (IRWD), Innoviva (INVA), OPKO Health (OPK), Organogenesis (ORGO), Inozyme Pharma (INZY), and Foghorn Therapeutics (FHTX). These companies are all part of the "pharmaceutical preparations" industry.
Geron (NASDAQ:GERN) and Amicus Therapeutics (NASDAQ:FOLD) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, community ranking, earnings and media sentiment.
In the previous week, Amicus Therapeutics had 10 more articles in the media than Geron. MarketBeat recorded 13 mentions for Amicus Therapeutics and 3 mentions for Geron. Geron's average media sentiment score of 0.68 beat Amicus Therapeutics' score of 0.46 indicating that Geron is being referred to more favorably in the media.
73.7% of Geron shares are owned by institutional investors. 3.1% of Geron shares are owned by insiders. Comparatively, 2.2% of Amicus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Geron has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.
Geron presently has a consensus price target of $6.10, indicating a potential upside of 60.10%. Amicus Therapeutics has a consensus price target of $17.50, indicating a potential upside of 82.86%. Given Amicus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Amicus Therapeutics is more favorable than Geron.
Amicus Therapeutics has higher revenue and earnings than Geron. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks.
Amicus Therapeutics received 37 more outperform votes than Geron when rated by MarketBeat users. Likewise, 73.50% of users gave Amicus Therapeutics an outperform vote while only 69.52% of users gave Geron an outperform vote.
Amicus Therapeutics has a net margin of -34.73% compared to Geron's net margin of -38,730.00%. Geron's return on equity of -68.16% beat Amicus Therapeutics' return on equity.
Summary
Amicus Therapeutics beats Geron on 11 of the 18 factors compared between the two stocks.
Get Geron News Delivered to You Automatically
Sign up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
